Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common blood pressure drug better protect hearts in obesity?

NCT ID NCT04519164

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This completed study tested whether eplerenone, a drug that blocks a hormone called aldosterone, improves blood flow and reduces scarring in the heart more than another drug, chlorthalidone, in 79 people with obesity and high blood pressure. Participants took one of the two drugs, and researchers used heart MRIs to measure changes. The goal was to see if eplerenone offers extra heart protection beyond just lowering blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eplerenone (a blood pressure drug) and chlorthalidone with potassium chloride (another blood pressure drug)
What this could lead to
If eplerenone works better, it could point to a more targeted way to protect the heart in people with obesity and high blood pressure.
What could go wrong
This is a small, completed Phase 4 trial with only 79 participants, so results may not apply to everyone. The drugs have known side effects like electrolyte imbalances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

79 people

The number who actually took part.

Started

Dec 2020

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. BMI ≥ 30 with at least one of the following, or BMI ≥ 25 with at least two of the following: 1. Untreated Hypertension: Stage I (BP 120-139/80-89 mmHg) or stage II (BP 140-159/90-99 mmHg). 2. Treated Hypertension: On one anti-hypertensive medication with BP\<140/90 mmHg and willing to undergo a 2-week washout of the medication before initiating eplerenone or chlorthalidone + KCl 3. Dysglycemia: Impaired fasting plasma glucose (100-125 mg/dL) or glycated A1c 5.7-6.4% 4. Dyslipidemia: Fasting triglyceride level \> 150 mg/dL and HDL\< 40 mg/dL in men or \<50 mg/dL in women. 2. Age between 18 and 70 years old Exclusion Criteria: * Estimated glomerular filtration rate \< 60 mL/min/1.73m2) * Serum potassium \> 5.2 mEq/L * Known diagnosis or treatment for type 1 or type 2 diabetes * Known history of CVD (myocardial infarction, heart failure, atrial fibrillation, or stroke) * EKG with ischemic ST-segment or T-wave changes or Q waves in more than one territorial lead or a left bundle branch block * Pregnancy (verified with a pregnancy test) or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome hypertensive disorder metabolic syndrome X Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Metabolic syndrome Overweight and obesity

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.